Conditions

This post was originally published on this site Patients with follicular lymphoma and marginal zone lymphoma who failed at least one prior therapy live significantly longer — more than two years — without their disease worsening when treated with a combination of Revlimid (lenalidomide) and Rituxan (rituximab), compared to Rituxan alone, a Phase 3 trial shows. The combination was also superior…

This post was originally published on this site Combining the immune checkpoint inhibitor Keytruda (pembrolizumab) with either a PARP inhibitor, chemotherapy, or hormone therapy led to promising signs of activity in metastatic castration-resistant prostate cancer (mCRPC) patients in a Phase 1b/2 trial, Merck — Keytruda’s developer — announced. The findings were presented at the 2019…

This post was originally published on this site Frying oil that has repeatedly been reheated to high temperatures — as can take place in deep frying of foods — may cause genetic changes that trigger the growth and spread of breast cancer, a study in a mouse model of the disease reports. The study, “Thermally…

This post was originally published on this site Combining anti-PD-L1 immunotherapies with agents that inhibit the DNA damage response (DDR) significantly enhances anti-tumor immunity and leads to rapid tumor disappearance in mouse models of small cell lung cancer (SCLC), a study reports. These preclinical findings suggest that adding DDR inhibitors, such as Lynparza (olaparib) or prexasertib, to immune checkpoint…

This post was originally published on this site After first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now recommended the use of Adcetris (brentuximab vedotin) as a second-line therapy for patients with CD30-positive cutaneous T-cell lymphomas (CTCL). This means that CTCL patients living in the U.K. may now have access to Adcetris…

This post was originally published on this site An application has been submitted seeking U.S. approval of Darzalex (daratumumab) in combination with standard pre-transplant therapy to treat newly diagnosed multiple myeloma patients who are eligible for a stem cell transplant. Janssen‘s supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) is for a combination of…

This post was originally published on this site Novocure has initiated a Phase 3 trial investigating its Tumor Treating Fields (TTFields) — a method that uses electric fields to disrupt cell division — in combination with Taxol (paclitaxel) as a treatment for ovarian cancer patients who are resistant to platinum-based chemotherapy. The trial — which…

This post was originally published on this site A new Prostate Cancer Foundation (PCF) collaboration with CURE Media Group, a multimedia platform, is expected to raise awareness of prostate cancer and enhance the scope and availability of disease information. Specifically, the PCF has joined CURE Media’s Strategic Alliance Partnership (SAP) program, which works to cultivate information-sharing…